Niagen Bioscience (NAGE) EBT (2010 - 2026)

Niagen Bioscience (NAGE) has 17 years of EBT data on file, last reported at $6.7 million in Q1 2026.

• On a quarterly basis, EBT rose 28.75% year-over-year to $6.7 million in Q1 2026; TTM through Mar 2026 was $19.7 million, a 35.11% increase from a year earlier, with the FY2025 full-year figure at $18.2 million, up 105.44% from the prior year.
• EBT for Q1 2026 stood at $6.7 million, up from $4.4 million in the prior quarter.
• Over the last five years, EBT for NAGE reached as high as $7.5 million in Q4 2024 and fell as low as -$11.7 million in Q2 2022.
• Historically, EBT has averaged -$878235.3 across 5 years, with a median of -$270000.0 in 2023.
• On a YoY basis, EBT climbed as much as 25013.33% in 2025 and fell as far as 40.89% in 2025.
• Year by year, EBT stood at -$1.6 million in 2022, then jumped by 82.9% to -$270000.0 in 2023, then soared by 2871.85% to $7.5 million in 2024, then slumped by 40.89% to $4.4 million in 2025, then soared by 52.24% to $6.7 million in 2026.
• Per Business Quant data, the three most recent EBT figures were $6.7 million in Q1 2026, $4.4 million in Q4 2025, and $4.8 million in Q3 2025.